Our studies indicated that the prognostic impact was TGFB2 mRNA-dependent using both the Cox proportional hazards model and the Kaplan–Meier analysis, suggesting that breast cancer patients with high levels of both TGFB2 and GDAP1 expression displayed significantly improved OS outcomes. The gene discussed is TGFB2; the disease is breast carcinoma.